Biocompatible implant for the timing of ovulation in mares

• US 5,545,408 A
• Filed: 06/15/1994
• Issued: 08/13/1996
• Est. Priority Date: 10/21/1991
• Status: Expired due to Term

• Current Assignee: Peptech Animal Health Pty., Limited
• Original Assignee: Peptide Technology Limited (Teva Pharmaceutical Industries Limited)
• Inventors: Souires, Edward L., Jochle, Wolfgang, Trigg, Timothy E.
• Primary Examiner(s): KRASS, FREDERICK F
• Application Number:
  US08/211,794
• Time in Patent Office: 790 Days
• Field of Search: 119/174, 514/12, 514/8, 514/13, 514/14, 514/15, 514/21, 424/422, 424/423, 424/425, 424/426
• US Class Current: 424/422
• CPC Class Codes: A61D 17/002 for detecting period of heat of animals, i.e. for detecting oestrus for humans A61B10/0012
• CPC Class Codes: A61K 38/09 Luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The disclosed invention relates to a method for controlling the timing of the ovulation of mares using an LHRH agonist, and to a biocompatible implant for use in such a method.

Claims

1. A method for the controlled induction of ovulation in mares comprising implanting into a mare which already has an ovarian follicle approaching maturation a solid biocompatible implant comprising a solid carrier and an effective amount of an agonist of LHRH so as to increase the level of LHRH agonist in the mare above that prevailing immediately before that implantation.

2. A method as claimed in claim 1 in which the LHRH agonist is Deslorelin.

3. A method as claimed in claim 1 in which the LHRH agonist is present in the implant in an amount of from 1.0 to 5.0 mg.

4. A method as claimed in claim 3 in which the LHRH agonist is present in the implant in an amount of 1.5 to 3.0 mg.

5. A method as claimed in claim 4 in which the LHRH agonist is present in the implant in an amount of 2.0 to 2.4 mg.

6. A method as claimed in claim 1 in which the solid carrier comprises a biologically absorbable inorganic salt and an organic tablet-release compound.

7. A method as claimed in claim 1 in which the implant is embedded subcutaneously into the mare.

8. A method as claimed in claim 7 in which the implant is embedded into the mare through a tubular needle inserted into the mare, the implant being pushed down the needle with an obturator as the needle is withdrawn.

9. A solid biocompatible implant for controlling the induction of ovulation in mares which already have an ovarian follicle approaching maturation, the implant comprising a biologically absorbable solid and from 1.0 to 5.0 mg of an agonist of LHRH, wherein said implant is substantially cylindrical having a diameter of from 0.5 to 5.0 mm and a length of from 1.0 to 6.0 mm.

10. A biocompatible implant as claimed in claim 9 in which the LHRH agonist is Deslorelin.

11. A biocompatible implant as claimed in claim 9 in which the LHRH agohist is present in the implant in an amount of from 1.5 to 3.0 mg.

12. A biocompatible implant as claimed in claim 9 in which the LHRH agonist is present in the implant in an amount of from 2.0 to 2.4 mg.

13. A biocompatible implant as claimed in claim 9 in which the solid carrier comprises a biologically absorbable inorganic salt and an organic tablet release compound.

14. A biocompatible implant as claimed in claim 13 in which the inorganic salt is selected from the group consisting of calcium phosphate dihydrate, calcium phosphate, sodium sulphate and calcium carbonate.

15. A biocompatible implant as claimed in claim 13 in which the organic tablet release compound is selected from the group consisting of a fatty acid and a hydrogenated vegetable oil.